We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Life Technologies Buys Instruments Distributor in Korea

By LabMedica International staff writers
Posted on 17 Jun 2013
Life Technologies Corp. More...
(Carlsbad, CA, USA) announced the acquisition of an instrument distributor Life Science Korea (LSK; Seoul, Republic of Korea).

LSK has been Life Technologies’' primary instrument distributor since 1994 and holds distribution rights to Applied Biosystems products, including next-generation sequencing instruments, Sanger sequencing systems, forensics, and polymerase chain reaction (PCR) products. LSK serves more than 1,000 customers in academia, government, pharmaceutical, biotech, hospitals, and applied markets. Under the acquisition terms, the LSK name will become part of Life Technologies Korea. No other terms of the deal were announced.

The combination of LSK and Life Technologies will continue to build a strong Life Technologies brand in Korea to stimulate fast and sustainable growth and be well positioned to take advantage of Korea’s focus on developing biotechnology. In the past five years, South Korea has shown solid growth in the biotechnology industry and with the Korean government's Bio-vision 2016 initiative, it is expected that the country will continue to invest heavily in the life sciences industry.

Life Technologies is a global biotechnology company with portfolio of 50,000 end-to-end solutions secured by more than 5,000 patents and licenses that span the following biologic spectrum-scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine, and agricultural research.

“The acquisition of LSK is in line with our go-direct strategy in South Korea and builds on our current capabilities and platforms in this important market,” said Mark Smedley, president of Life Technologies, Asia Pacific, Japan region. “The combination of Life Technologies Korea and LSK, bolstered by our recent acquisition of consumables distributor KDR, enables us to offer one channel to serve the many different needs of our South Korean customers and to create a superior purchasing experience.”

Related Links:
Life Technologies
Life Science Korea



New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Aspiration System
VACUSAFE
New
POC Immunoassay Analyzer
Procise DX
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.